Oral Bio-equivalence Study

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 29, 2015

Primary Completion Date

January 15, 2016

Study Completion Date

January 15, 2016

Conditions
BioequivalenceSafety
Interventions
DRUG

Fingolimod 0.5 mg capsules- Test drug

An oral dose of the assigned formulation (3 capsules) will be administered in the morning to subjects with about 240 mL of water at ambient temperature according to the randomization scheme.

Trial Locations (1)

H3P 3H5

Algorithme Pharma Inc., Mount Royal

Sponsors
All Listed Sponsors
lead

Alembic Pharmaceuticals Ltd.

INDUSTRY

NCT05145621 - Oral Bio-equivalence Study | Biotech Hunter | Biotech Hunter